Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

PENN begins clinical trial of newest technology to treat thoracic aortic aneurysms

17.02.2005


A clinical trial is underway at the Hospital of the University of Pennsylvania (HUP) to study the safety and effectiveness of an endovascular medical device to treat life-threatening thoracic aortic aneurysms. Ronald Fairman, MD, Chief of Vascular Surgery at HUP, is leading the study at Penn and is one of 35 principal investigators in North America to participate in this landmark trial.



Thoracic aortic aneurysms (TAAs) occur when a section of the aorta – the body’s largest artery that carries blood out of the heart and into the organs of the body – weakens and bulges outward like a balloon in the section of the artery that runs down the chest. Each year, more than 20,000 patients in the United States are diagnosed with TAA. Aortic aneurysms – including thoracic and abdominal aortic aneurysms – remain the 13th major cause of death in this country, accounting for nearly 15,000 deaths annually.

"The STARZ-TX2 trial is groundbreaking and excellent news for patients diagnosed with descending thoracic aortic aneurysms," says Dr. Fairman. "Surgery can be life-threatening for many of these patients and a ’wait-and-see’ approach is often not an option because patients are at an increased risk of an aortic rupture. A non-surgical approach to treating this life-threatening disease could benefit thousands of lives."


The clinical trial, called STARZ-TX2 (Study of Thoracic Aortic Aneurysm Repair with the Zenith® TX2™ Thoracic TAA Endovascular Graft), is open to patients diagnosed with a descending thoracic aortic aneurysm. STARZ-TX2 will compare the outcomes of patients treated with open surgery to patients treated with the Zenith TX2 Thoracic TAA Endovascular Graft, manufactured by Cook Incorporated.

Specifically, the trial will assess device performance, as well as patient survival and aneurysm rupture rates in the surgical and endovascular treatment groups, over a 12-month period.

The trial will enroll 275 patients at up to 35 medical institutions in the United States and Canada. Additional trial sites in Japan, Australia and Europe also will participate.

Currently, surgical repair is the standard of care for the treatment of TAAs. Surgical repair requires a surgeon to open the chest cavity, clamp off the aorta and sew a surgical graft in place to prevent an aneurysm from rupturing. Open surgical repairs carry high health risks for many older patients, who may also suffer from other significant medical conditions such as heart disease, lung disease, diabetes or hypertension.

The Zenith TX2 system requires an incision to insert the graft’s hydrophilic, kink-resistant delivery system into the femoral artery in the leg. Once the system is guided into position through the patient’s arteries under fluoroscopy, a one- or two-piece, fabric-covered, self-expanding stent graft is placed inside the weakened section of the thoracic aorta to relieve pressure on the aneurysm, helping to reduce the risk of rupture.

Endovascular treatment of aortic aneurysms has been a common practice for the past 10 years in the United States, Europe and Asia. During that time, significant improvements in treatment outcomes have been observed among patients treated with endovascular devices as compared with standard open surgery. Current endovascular treatments are marketed worldwide for the treatment of abdominal aortic aneurysms.

The major cause of thoracic aortic aneurysms is a hardening of the arteries, a condition in which fatty deposits adhere to the walls of the arteries, which become less elastic and weaker as a result. Major risk factors leading to a hardening of the arteries include smoking and high blood pressure as well as genetics. Other possible causes of TAA include trauma to the aorta and congenital diseases such as Marfan’s syndrome.

Ed Federico | EurekAlert!
Further information:
http://www.uphs.upenn.edu

More articles from Health and Medicine:

nachricht Satellites, airport visibility readings shed light on troops' exposure to air pollution
09.12.2016 | Veterans Affairs Research Communications

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Electron highway inside crystal

Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.

Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Researchers identify potentially druggable mutant p53 proteins that promote cancer growth

09.12.2016 | Life Sciences

Scientists produce a new roadmap for guiding development & conservation in the Amazon

09.12.2016 | Ecology, The Environment and Conservation

Satellites, airport visibility readings shed light on troops' exposure to air pollution

09.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>